Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy
A Multicenter, Randomized Clinical Trial

Pär I. Johansson1,2, Peter Søe-Jensen3, Morten H. Bestle2,4, Niels E. Clausen5, Klaus T. Kristiansen6, Theis Lange7, Jakob Stensballe1,8, and Anders Perner2,9

1Department of Clinical Immunology, 2Department of Anaesthesiology, Center of Head and Orthopaedics, 3Department of Intensive Care, Copenhagen University Hospital–Rigshospitalet, Copenhagen, Denmark; 4Department of Intensive Care, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark; 5Department of Intensive Care, Copenhagen University Hospital–North Zealand, Copenhagen, Denmark; 6Department of Intensive Care, Copenhagen University Hospital–Bispebjerg and Frederiksberg, Copenhagen, Denmark; 7Department of Intensive Care, Copenhagen University Hospital–Amager and Hvidovre, Copenhagen, Denmark; and 8Department of Clinical Medicine and 9Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark

ORCID ID: 0000-0001-9778-5964 (P.I.J.).

Abstract

Rationale: The mortality in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who require mechanical ventilation remains high, and endotheliopathy has been implicated.

Objectives: To determine the effect of prostacyclin infusion in mechanically ventilated patients infected with SARS-CoV-2 with severe endotheliopathy.

Methods: We conducted a multicenter, randomized clinical trial in adults infected with coronavirus disease (COVID-19) who required mechanical ventilation and had a plasma level of thrombomodulin >4 ng/ml; patients were randomized to 72-hour infusion of prostacyclin 1 ng/kg/min or placebo.

Measurements and Main Results: The main outcome was the number of days alive without mechanical ventilation at 28 days. Key secondary outcomes were 28-day mortality and serious adverse events within 7 days. Eighty patients were randomized (41 prostacyclin and 39 placebo). The median number of days alive without mechanical ventilation at 28 days was 16.0 days (SD, 12) versus 5.0 days (SD, 10) (difference of the medians, 10.96 days; 95% confidence interval [CI], −5 to 21; P = 0.07) in the prostacyclin and the placebo groups, respectively. The 28-day mortality was 21.9% versus 43.6% in the prostacyclin and the placebo groups, respectively (risk ratio, 0.50; 95% CI, 0.24 to 0.96; P = 0.06). The incidence of serious adverse events within 7 days was 2.4% versus 12.8% (risk ratio, 0.19; 95% CI, 0.001 to 1.11; P = 0.10) in the prostacyclin and the placebo groups, respectively.

Conclusions: Prostacyclin was not associated with a significant reduction in the number of days alive and without mechanical ventilation within 28 days. The point estimates, however, favored the prostacyclin group in all analyses, including 28-day mortality, warranting further investigation in larger trials.

Clinical trial registered with www.clinicaltrials.gov (NCT 04420741); EudraCT Identifier: 2020-001296-33.

Keywords: COVID-19; endotheliopathy; thrombomodulin; prostacyclin
As of October 11, 2021, more than 236 million people have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection globally, with more than 4.8 million deaths (1). To date, only glucocorticoids and IL-6 receptor antagonists are known to improve survival among those severely ill with coronavirus disease (COVID-19) (2–4). Mortality rates around 30–40% have been reported in patients with critical COVID-19 and are highest in those requiring invasive mechanical ventilation (5). In autopsy series, microvascular thrombosis of the pulmonary vasculature has frequently been observed (6–9). These findings are in alignment with the observation of endotheliopathy as a prominent feature of the COVID-19 acute respiratory distress syndrome pathophysiology (10–12). Similar to findings in patients with varying degrees of other severe infections (13), the level of circulating soluble thrombomodulin (sTM) was significantly associated with mortality in patients with COVID-19 (10). Thrombomodulin is a key member of the anticoagulant protein C system, and its cleavage from the endothelium may be involved in the pathophysiology of the prothrombotic phenotype observed in patients with COVID-19 (14).

Prostacyclin (PGI₂) is an endogenous prostanoid formed and released by endothelial cells, with paracrine function including dose-dependent vasodilation and platelet inhibition being the rationale for its use as a pharmacological therapy for patients with primary pulmonary hypertension and critical limb ischemia (15, 16). In the new millennium, multiple beneficial effects of prostacyclin on the endothelium were reported (17–23). In clinical trials in critically ill patients in the ICU, including those with septic shock, the use of low-dose (0.5–2.0 ng/ml/kg) continuous infusion of prostacyclin as compared with placebo was safe (24–26).

The aim of the present randomized controlled trial was, therefore, to investigate the safety and the efficacy of prostacyclin as compared with placebo on days alive without mechanical ventilation within 28 days in mechanically ventilated patients with COVID-19 with documented endotheliopathy, as measured by a circulating sTM level of ≥4 ng/ml (27).
Outcomes
The primary outcome was the number of days alive without mechanical ventilation within 28 days from randomization. Secondary outcomes included 28- and 90-day mortality, mean daily Sequential Organ Failure Assessment (SOFA) score in the ICU up to Day 90, days alive without vasopressor in the ICU within 28 and 90 days, days alive without mechanical ventilation in the ICU within 90 days, days without renal replacement in the ICU within 28 and 90 days, number of serious adverse reactions within the first 7 days, and number of serious adverse events within the first 7 days.

Treatment
Prostacyclin (1 ng/kg/min) or placebo (equal volume of saline) was administered as a continuous intravenous infusion for 72 hours.

Procedures
All patients were assessed from randomization (Day 1) through Day 90. Adverse events were recorded from time of signature of informed consent and graded according to the Common Terminology Criteria for Adverse Events, version 5.0. Causality was assessed by the investigators for serious adverse events.

Statistical Analyses
Sample size estimation was based on a power calculation using the data from a randomized clinical trial in patients with acute respiratory distress syndrome (NTC 02622724) (28).

The mean number of days alive and free of mechanical ventilation was 10 days, with an SD of 3. If the true effect of the intervention is an increase in days alive and free of mechanical ventilation of 20% (relative), providing the trial with 80% power to detect this difference at a significance level of 0.05 will require a sample size of 70 patients. To allow for an ~10% dropout, 80 patients were included (clinicaltrials.gov identifier: NCT04420741).

All analyses were performed in the intention-to-treat (ITT) population, defined as all randomized patients. The primary outcome was compared using the Wilcoxon test and differences expressed as changes in medians with non-parametric-based bootstrapped 95% CI.

Ethics
The protocol was approved by the Danish regional ethics committee (H-20026049) and the Danish Medicines Agency (Eudract no. 2020-001296-33). The study was registered at clinicaltrials.gov, NCT 04420741. The study was conducted at five university hospital ICUs in the Capital Region of Denmark in accordance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. Written informed consent, in accordance with national legislation, was obtained from the patient’s surrogate and confirmed by the patients who regained consciousness.

Results
Patients
Between June 15, 2020, and January 25, 2021, 138 patients were screened and 80 randomized, among whom 41 were allocated to prostacyclin and 39 to placebo; five patients discontinued the intervention (Figure 1). Baseline characteristics were generally well balanced between the intervention groups (Table 1).

Primary Outcome
In the ITT population, the number of days alive without mechanical ventilation at 28 days was a median of 16.0 days (SD, 12) versus 5.0 days (SD, 10) (difference of the medians, 10.96; 95% CI, −5 to 21; P = 0.07) in the prostacyclin group versus the placebo group, respectively (Table 2).

Table 1. Characteristics of the Patients at Baseline according to Treatment Assignment

|                        | Prostacyclin Group (n = 41) | Placebo Group (n = 39) |
|------------------------|-----------------------------|------------------------|
| Age, yr                | 68 (60–73)                  | 66 (57–75)             |
| Sex                    |                             |                        |
| M                      | 30 (73)                     | 23 (59)                |
| F                      | 11 (27)                     | 16 (41)                |
| Ethnicity              |                             |                        |
| White                  | 38 (93)                     | 37 (95)                |
| Asian                  | 0 (0)                       | 2 (5)                  |
| Black                  | 2 (5)                       | 0 (0)                  |
| Hispanic               | 1 (2)                       | 0 (0)                  |
| Other                  | 0 (0)                       | 0 (0)                  |
| Admitted from          |                             |                        |
| Emergency room         | 9 (22)                      | 11 (28)                |
| Ward                   | 28 (68)                     | 27 (69)                |
| Operating room/postoperative care | 1 (2) | 0 (0) |
| Other ICU              | 3 (7)                       | 1 (3)                  |
| Comorbidity            |                             |                        |
| Chronic cardiovascular disease | 26 (63) | 23 (59) |
| Chronic respiratory disease | 6 (15) | 4 (10) |
| Metastatic cancer      | 1 (2)                       | 0 (0)                  |
| Hematological cancer   | 1 (2)                       | 3 (8)                  |
| End-stage renal disease| 1 (2)                       | 1 (3)                  |
| Clinical observations at inclusion |                     |                        |
| SOFA score at day of randomization | 7 (6–9) | 7 (6–9) |
| Lowest SBP 24 h before randomization, mm Hg | 85 (77–93) | 82 (74–89) |
| Vasopressor 24 h before randomization, mm Hg | 37 (90) | 34 (87) |
| RRT 24 h before randomization | 1 (2) | 2 (5) |
| Acute surgery 24 h before randomization | 1 (2) | 0 (0) |
| Mechanical ventilation before screening, h | 12 (1–21) | 15 (9–20) |
| ICU admission before screening, h | 28 (11–62) | 21 (12–44) |

Definition of abbreviations: RRT = renal replacement therapy; SBP = systolic blood pressure; SOFA = Sequential Organ Failure Assessment.
Data are shown as n (%) or median (interquartile range).
Secondary Outcomes
The 28-day mortality was 21.9% in the prostacyclin group versus 43.6% in the placebo group (risk ratio, 0.50; 95% CI, 0.24 to 0.96; P = 0.06). The 90-day mortality was 31.7% versus 48.7% (risk ratio, 0.65; 95% CI, 0.36 to 1.12; P = 0.17) in the prostacyclin group versus the placebo group, respectively (Figure 2). The SOFA score was 5.7 versus 6.7 (adjusted difference, 1.1; 95% CI, 0.28 to 1.92; P = 0.009) in the prostacyclin group versus the placebo group, respectively. The median days alive and free of renal replacement therapy in the ICU within 28 days was 28 days versus 21 days (difference of the medians, 7 days; 95% CI, 0 to 12; P = 0.06) and at 90 days was 90 versus 79 days (difference of the medians, 11 days; 95% CI, −2.5 to 74; P = 0.08) in the prostacyclin group versus the placebo group, respectively. The median days alive and free of vasopressors in the ICU within 28 days was 22 days versus 13 days (difference of the medians, 9; 95% CI, −18 to 1.5; P = 0.14) and within 90 days was 84 days versus 59 days (difference of the medians, 25 days; 95% CI, −3 to 75.5; P = 0.16) in the prostacyclin group versus the placebo group, respectively. The number of days alive and free of mechanical ventilation within 90 days was 77 days versus 13 days (difference of the medians, 64 days; 95% CI, −6 to 80; P = 0.10) in the prostacyclin group versus the placebo group, respectively.

Safety Outcomes
No significant difference between groups was found regarding serious adverse events and reactions within 7 days. The incidence was 2.4% versus 12.8% (risk ratio, 0.19; 95% CI, 0.001–1.11; P = 0.10) in the prostacyclin group versus the placebo group, respectively (Table 2).

Discussion
In this multicenter randomized trial, we did not find a statistically significantly difference in the number of days alive without mechanical ventilation within 28 days among patients with COVID-19 allocated to prostacyclin or placebo for 72 hours. The point estimate, however, did favor the prostacyclin group; the same was found for the secondary outcomes, among which the mean daily SOFA scores were statistically significantly lower in the prostacyclin group than in the placebo group. Prostacyclin has been reported to have several beneficial effects on the endothelium, including synthesizing endothelial glycosalys constituents (17, 18), inducing reendothelialization of damaged vessels (20), improving tight-junction integrity (19), and attenuating the inflammatory hit on the endothelium (21, 22). In alignment with this, the patients with COVID-19 included in this study were characterized by severe pulmonary failure requiring mechanical ventilation and severe endotheliopathy, as evidenced by circulating sTM levels at ≥4 ng/ml (10), and we speculate that prostacyclin may be responsible for the results observed. Improvement in clinical condition of patients with severe COVID-19 secondary to infusion of prostacyclin was also recently reported by Moezinia and colleagues, who, in a case series of three patients, found that 5-day continuous infusion of low-dose prostacyclin was associated with decreasing oxygen requirements, increasing PaO₂/FiO₂ ratio, and normalization of heart rate up to 48 hours, suggesting an improvement in vital organ function (29).

We found no difference in serious adverse events or reactions between the groups, indicating that prostacyclin at a dose of 1 ng/kg/min may be safe in critically ill patients with COVID-19 and severe endotheliopathy. These findings are corroborated by results from randomized clinical trials in patients receiving liver transplantation (24) and patients with septic shock (26).
The limited sample size, rendering the study underpowered, precludes firm conclusions about prostacyclin’s effects on the primary and secondary outcome measures. Also, all patients were enrolled in ICUs in the Capital Region of Denmark only, which may reduce the generalizability of the results. Furthermore, a potential effect of coenrollment of the patients in other interventional clinical trials cannot be excluded. Lastly, the preplanned statistical methods used to investigate the mortality, CI (generalized linear model) and P value (Fisher exact test), may lead to different results in borderline cases, such as here, and this is a limitation for the interpretation of the results. The observed risk ratio of 0.5 and the trend observed for lower mortality suggest that a larger study or a meta-analysis of studies will be required to demonstrate a beneficial effect of the intervention.

In conclusion, we did not observe a statistically significant difference in the number of days alive without mechanical ventilation within 28 days among mechanically ventilated patients with COVID-19 and severe endotheliopathy allocated to infusion of prostacyclin or placebo for 72 hours. The point estimates favored the prostacyclin group in all analyses, including mortality. Collectively, the data warrant a large randomized clinical trial of prostacyclin in mechanically ventilated patients with COVID-19 with severe endotheliopathy owing to the continued considerable unmet medical need.

**References**

1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [accessed 2021 Oct 11]. Available from: covid19.who.int.
2. Horby P, Lim WS, Emberson JR, Mathur M, Bell JL, Linsell L, et al.; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med* 2021;384:699–704.
3. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al.; REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. *N Engl J Med* 2021;384:1491–1502.
4. Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al.; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic...
corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020;324:1330–1341.
5. Grasselli G, Cattaneo E, Florio G, Ippolito M, Zanella A, Cortegiani A, et al. Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review. Crit Care 2021;25:115.
6. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020;20:1135–1140.
7. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Diffuse alveolar damage in SARS-CoV-2 associated pulmonary edema. Lancet 2020;395:1033–1035.
8. Dorward DA, Russell CD, Um IH, Elshani M, Armstrong SD, Penrice-Randall R, et al. Tissue-specific immunopathology in fatal COVID-19. Am J Respir Crit Care Med 2021;203:192–201.
9. Mangalmurti NS, Reilly JP, Cines DB, Meyer NJ, Hunter CA, Vaughan AE. Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. Int Immunopharmacol 2005;5:437–459.
10. Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020;7:e575–e582.
11. Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians. Respir Med 2021;176:106239.
12. Matthay MA, Leligdowicz A, Liu KD. Biological mechanisms of COVID-19 acute respiratory distress syndrome. Am J Respir Crit Care Med 2020;202:1489–1491.
13. Johansen ME, Johansson PI, Ostrowski SR, Bestle MH, Hein L, Jensen D, et al. Profound endothelial damage predicts impending organ failure and death in sepsis. Semin Thromb Hemost 2015;41:16–25.
14. Loghmani H, Conway EM. Exploring traditional and nontraditional roles for thrombomodulin. Blood 2018;132:148–158.
15. Robbins SL, Kumar V, Cotran RS. Pathologic basis of disease, 8th ed. Philadelphia: Saunders; 2010.
16. Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol 2019;176:1038–1050.
17. Bruggeman LA, Pellicoro JA, Horigan EA, Klotman PE. Thromboxane and prostacyclin differentially regulate murine extracellular matrix gene expression. Kidney Int 1993;43:1219–1225.
18. Sussmann M, Sarbia M, Meyer-Kirchrahn J, Nüsing RM, Schror K, Fischer JW. Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins. Circ Res 2004;94:582–600.